-
Loading metrics
Open Access
Peer-reviewed
Research Article
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
-
Laura E. MacConaill,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Catarina D. Campbell,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Sarah M. Kehoe,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Adam J. Bass,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Charles Hatton,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Lili Niu,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Matt Davis,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Keluo Yao,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Megan Hanna,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Chandrani Mondal,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Lauren Luongo,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Caroline M. Emery,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Alissa C. Baker,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Juliet Philips,
Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Deborah J. Goff,
Affiliations Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Michelangelo Fiorentino,
Affiliation Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Mark A. Rubin,
Affiliation Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Kornelia Polyak,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Jennifer Chan,
Affiliation The Broad Institute, Cambridge, Massachusetts, United States of America
⨯ -
Yuexiang Wang,
Affiliation Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Jonathan A. Fletcher,
Affiliation Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Sandro Santagata,
Affiliation Department of Neuro-Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Gianni Corso,
Affiliations Surgical Oncology and Department of Human Pathology and Oncology, University of Siena, Siena, Italy, Translational Research Laboratory Istituto Toscano Tumori, Siena, Italy
⨯ -
Franco Roviello,
Affiliations Surgical Oncology and Department of Human Pathology and Oncology, University of Siena, Siena, Italy, Translational Research Laboratory Istituto Toscano Tumori, Siena, Italy
⨯ -
Ramesh Shivdasani,
Affiliation Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Mark W. Kieran,
Affiliation Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Keith L. Ligon,
Affiliations Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
Charles D. Stiles,
Affiliations Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America
⨯ -
William C. Hahn,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, The Broad Institute, Cambridge, Massachusetts, United States of America
⨯ -
Matthew L. Meyerson,
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, The Broad Institute, Cambridge, Massachusetts, United States of America
⨯ - [ ... ],
-
Levi A. Garraway
* E-mail: Levi_Garraway@dfci.harvard.edu
Affiliations Center for Cancer Genome Discovery, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, United States of America, The Broad Institute, Cambridge, Massachusetts, United States of America
⨯ - [ view all ]
- [ view less ]
Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples
- Laura E. MacConaill,
- Catarina D. Campbell,
- Sarah M. Kehoe,
- Adam J. Bass,
- Charles Hatton,
- Lili Niu,
- Matt Davis,
- Keluo Yao,
- Megan Hanna,
- Chandrani Mondal
- Published: November 18, 2009
- https://doi.org/10.1371/journal.pone.0007887